Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir/rilpivirine use.

Dorcas MaruapulaNatasha O MorakaOntlametse T BarengPatrick T MokgethiWonderful T ChogaKaelo K SeatlaNametso KelentseCatherine K KoofhethilleBoitumelo J L ZuzeTendani GaolatheMolly Pretorius-HolmeJoseph MakhemaVlad NovitskyRoger ShapiroSikhulile MoyoShahin LockmanSimani Gaseitsiwe

Published in: The Journal of antimicrobial chemotherapy (2023)

RPV-RAMs were present in 10.7% of ART-naive and 13.7% of ART-suppressed PWH in Botswana. The most common RPV-RAM in both groups was E138A. Since individuals with the E138A mutation may be more likely to fail cabotegravir/rilpivirine, monitoring RPV-RAMs will be crucial for effective cabotegravir/rilpivirine implementation in this setting.

Keyphrases

hiv infected patients
hiv infected
antiretroviral therapy
healthcare
primary care
quality improvement